Under the deal, Pfizer acquired a portion of Baxter’s facility in Orth, Austria, which manufactures meningitis vaccine, NeisVac-C as well as the encephalitis vaccine, FSME-IMMUN/TicoVac.
NeisVac-C is a vaccine which helps protect against meningitis caused by group C meningococcal meningitis (MenC), while FSME-IMMUN helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.
Pfizer Vaccines president and general manager Susan Silbermann said: "NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines.
"These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases."
Kirkland & Ellis is the legal advisor and Credit Suisse Securities (USA) served as the financial advisor for Pfizer in the transaction.
Image: Pfizer world headquarters. Photo: courtesy of Jim.henderson.